EUVIMEDEUVIMED entdecken
Crossref

Compound‐42 alleviates acute kidney injury by targeting RIPK3‐mediated necroptosis

Xiao-Yan He, Fang Wang, Xiao-Guo Suo, Ming-Zhen Gu, Jia-Nan Wang, Chuan-Hui Xu, Yu-Hang Dong, Yuan He, Yao Zhang, Ming-Lu Ji, Ying Chen, Meng-Meng Zhang und 8 weitere

British Journal of Pharmacology · 2023

DOI: 10.1111/bph.16152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2023. Verfasst von Xiao-Yan He und 19 weiteren Autor:innen. Beteiligte Einrichtung: Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical Univer…. Hauptthemen laut MEDLINE: Cisplatin, Acute Kidney Injury. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Necroptosis plays an essential role in acute kidney injury and is mediated by receptor‐interacting protein kinase 1 (RIPK1), receptor‐interacting protein kinase 3 (RIPK3), and mixed lineage kinase domain‐like pseudokinase (MLKL). A novel RIPK3 inhibitor, compound 42 (Cpd‐42) alleviates the systemic inflammatory response. The current study was designed to investigate whether Cpd‐42 exhibits protective effects on acute kidney injury and reveal the underlying mechanisms. Experimental Approach The effects of Cpd‐42 were determined in vivo through cisplatin‐ and ischaemia/reperfusion (I/R)‐induced acute kidney injury and in vitro through cisplatin‐ and hypoxia/re‐oxygenation (H/R)‐induced cell damage. Transmission electron microscopy and periodic acid–Schiff staining were used to identify renal pathology. Cellular thermal shift assay and RIPK3‐knockout mouse renal tubule epithelial cells were used to explore the relationship between Cpd‐42 and RIPK3. Molecular docking and site‐directed mutagenesis were used to determine the binding site of RIPK3 with Cpd‐42. Key Results Cpd‐42 reduced human proximal tubule epithelial cell line (HK‐2) cell damage, necroptosis and inflammatory responses in vitro. Furthermore, in vivo, cisplatin‐ and I/R‐induced acute kidney injury was alleviated by Cpd‐42 treatment. Cpd‐42 inhibited necroptosis by interacting with two key hydrogen bonds of RIPK3 at Thr94 and Ser146, which further blocked the phosphorylation of RIPK3 and mitigated acute kidney injury. Conclusion and Implications Acting as a novel RIPK3 inhibitor, Cpd‐42 reduced kidney damage, inflammatory response and necroptosis in acute kidney injury by binding to sites Thr94 and Ser146 on RIPK3. Cpd‐42 could be a promising treatment for acute kidney injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinAcute Kidney InjuryMiceAnimalsHumansNecroptosisMolecular Docking SimulationProtein KinasesMice, KnockoutApoptosisReceptor-Interacting Protein Serine-Threonine Kinases

Stichwörter der Autor:innen

Cpd-42RIPK3 inhibitoracute kidney injurynecroptosis

Substanzen

CisplatinProtein KinasesRIPK3 protein, humanReceptor-Interacting Protein Serine-Threonine Kinases

Autor:innen und Institutionen

  • Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, The Key Laboratory of Anti-inflammatory of Immune Medicines, Min…
  • Department of Pharmacy, Lu'an Hospital of Anhui Medical University, Lu'an People's Hospital of Anhui Province, Lu'an, China.
  • Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China.
  • School of Basic Medical Sciences, Anhui Medical University, Hefei, China.
  • School of Pharmacy, Second Military Medical University, Shanghai, China.

ORCID-Profile: Chun-Lin Zhuang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

He, X. Y., Wang, F., Suo, X. G., Gu, M. Z., Wang, J. N., Xu, C. H., Dong, Y. H., He, Y., Zhang, Y., Ji, M. L., Chen, Y., Zhang, M. M., Fan, Y. G., Wen, J. G., Jin, J., Wang, J., Li, J., Zhuang, C. L., Liu, M. M., & Meng, X. M. (2023). Compound‐42 alleviates acute kidney injury by targeting RIPK3‐mediated necroptosis. British Journal of Pharmacology. https://doi.org/10.1111/bph.16152

Vancouver

He XY, Wang F, Suo XG, Gu MZ, Wang JN, Xu CH, et al. Compound‐42 alleviates acute kidney injury by targeting RIPK3‐mediated necroptosis. British Journal of Pharmacology. 2023. doi:10.1111/bph.16152

BibTeX
@article{He2023,
  author = {He, Xiao-Yan and Wang, Fang and Suo, Xiao-Guo and Gu, Ming-Zhen and Wang, Jia-Nan and Xu, Chuan-Hui and Dong, Yu-Hang and He, Yuan and Zhang, Yao and Ji, Ming-Lu and Chen, Ying and Zhang, Meng-Meng and Fan, Yin-Guang and Wen, Jia-Gen and Jin, Juan and Wang, Jie and Li, Jun and Zhuang, Chun-Lin and Liu, Ming-Ming and Meng, Xiao-Ming},
  title = {Compound‐42 alleviates acute kidney injury by targeting RIPK3‐mediated necroptosis},
  journal = {British Journal of Pharmacology},
  year = {2023},
  doi = {10.1111/bph.16152}
}
Kostenlos starten →